Can we measure long-term treatment effects in multiple sclerosis?

Nature Reviews Neurology

Volumn 11, Issue 3, 2015, Pages 176-182

  Sormani, Maria Pia ^a   Bruzzi, Paolo ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; INTERFERON BETA SERINE; PLACEBO;

CLINICAL STUDY; DISABILITY; DISEASE COURSE; HUMAN; MORTALITY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STATISTICAL ANALYSIS; STUDY DESIGN; TREATMENT DURATION; TREATMENT OUTCOME; INFECTIOUS DISEASE MEDICINE; PROCEDURES; TIME;

HUMANS; INFECTIOUS DISEASE MEDICINE; MULTIPLE SCLEROSIS; TIME; TREATMENT OUTCOME;

EID: 84924680863     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2014.237     Document Type: Review

References (30)

1. [No authors listed] Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43, 655-661 (1993
2. Jacobs, L. D., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39, 285-294 (1996
3. [No authors listed] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352, 1498-1504 (1998
4. Pritchard, K. I. Should observational studies be a thing of the past?. J. Natl Cancer Inst. 100, 451-452 (2008
5. Hernan, M. A., Hernandez-Diaz, S., Werler, M. M. & Mitchell, A. A. Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am. J. Epidemiol. 155, 176-184 (2002
6. Inusah, S., et al. Assessing changes in relapse rates in multiple sclerosis. Mult. Scler. 16, 1414-1421 (2010
7. Sormani, M. P., et al. Will Rogers phenomenon in multiple sclerosis. Ann. Neurol. 64, 428-433 (2008
8. Shirani, A., et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 308, 247-256 (2012
9. Tedeholm, H., et al. Time to secondary progression in patients with multiple sclerosis treated with first generation immunomodulating drugs. Mult. Scler. 19, 765-774 (2013
10. Drulovich, J., et al. Interferon-beta and disability progression in relapsing-remitting multiple sclerosis. Clin. Neurol. Neurosurg. 115 (Suppl 1), S65-S69 (2013
11. Trojano, M., et al. New natural history of interferon β treated relapsing multiple sclerosis. Ann. Neurol. 61, 300-306 (2007
12. Austen, P. C. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav. Res. 46, 399-424 (2011
13. Trojano, M., et al. Real-life impact of early interferonβ therapy in relapsing multiple sclerosis. Ann. Neurol. 66, 513-520 (2009
14. Renoux, C. & Suissa, S. Immortal time bias in the study of effectiveness of interferon-β in multiple sclerosis. Ann. Neurol. 64, 109-110 (2008
15. Lin, D. Y., Psaty, B. M. & Krommal, R. A. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 54, 948-963 (1998
16. Schneeweiss, S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol. Drug Saf. 15, 291-303 (2006
17. Brumback, B. A., Hernán, M. A., Haneuse, S. J. & Robins, J. M. Sensitivity analyses for unmeasured confounding assuming a marginal structural model for repeated measures. Stat. Med. 23, 749-767 (2004
18. Bergamaschi, R., et al. Immunomodulatory therapies delay disease progression in multiple sclerosis. Mult. Scler. http://dx.doi.org/10.1177/1352458512445941
19. Bergamaschi, R., et al. Early prediction of the long term evolution of multiple sclerosis: the Bayesian risk estimate for multiple sclerosis (BREMS) score. J. Neurol. Neurosurg. Psychiatry 78, 757-759 (2007
20. Robins, J. M. & Finkelstein, D. M. Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 56, 779-788 (2000
21. Seaman, S. R. and White, I. R. Review of inverse probability weighting for dealing with missing data. Stat. Methods Med. Res. 22, 278-295 (2013
22. Brown, M. G., et al. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?. Neurology 69, 1498-1507 (2007
23. Veugelers, P. J., et al. Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation. Mult. Scler. 15, 1286-1294 (2009
24. Ebers, G. C., et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J. Neurol. Neurosurg. Psychiatry 81, 907-912 (2010
25. Bermel, R. A., et al. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. Mult. Scler. 16, 588-596 (2010
26. Rudick, R. A., et al. Estimating long-Term effects of disease modifying drug therapy in multiple sclerosis. Mult. Scler. 11, 626-634 (2005
27. Kappos, L., et al. Long-Term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 67, 944-953 (2006
28. Goodin, D. S., et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. Neurology 78, 1315-1322 (2012
29. Poser, C. M., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13, 227-231 (1983
30. McDonald, W. I., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50, 121-127 (2001